3 Branded Generics, Life Sciences Services and Glycol Stocks With a Strong Future Roadmap: Alkem Laboratories, Indegene and India Glycols

Alkem Rs 5,050.00, P/E 28.43. Indegene Rs 598.30, P/E 35.20. India Glycols Rs 331.95, P/E 7.58. Closing prices of 14 Oct 2026.

Updated: 19 Oct 2026 • 9:43 am

Posted by:

3 Branded Generics, Life Sciences Services and Glycol Stocks With a Strong Future Roadmap: Alkem Laboratories, Indegene and India Glycols

Quick Answer

Branded generics, life sciences services and glycol stocks with the clearest long-term roadmaps today include Alkem in branded generics in India along with generic exports and a presence in international markets, Indegene in commercial, medical and regulatory services for life sciences and pharma companies and India Glycols in glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock. FY26 revenue growth was 13.7% at Alkem, 21.6% at Indegene and 11.5% at India Glycols. P/E stands at 28.43 for Alkem (industry 37.59), 35.20 for Indegene (industry 62.79) and 7.58 for India Glycols (industry 54.53). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Branded generics, life sciences services and glycol stocks give investors exposure to medicines, drug-industry services and renewable-based chemicals. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three branded generics, life sciences services and glycol stocks: Alkem Laboratories for branded generics in India along with generic exports and a presence in international markets, Indegene for commercial, medical and regulatory services for life sciences and pharma companies and India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Branded Generics, Life Sciences Services and Glycol Stocks?

Branded generics, life sciences services and glycol stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Branded Generics, Life Sciences Services and Glycol Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three branded generics, life sciences services and glycol stocks as of the 14 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Alkem Laboratories	5,050.00	62,663	28.43	37.59	16.66%	0.15
Indegene	598.30	14,110	35.20	62.79	12.78%	0.05
India Glycols	331.95	2,397	7.58	54.53	9.98%	0.58

Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Branded Generics, Life Sciences Services and Glycol Stocks Have a Strong Roadmap in India?

Branded generics, life sciences services and glycol stocks have a strong roadmap in India because branded medicine demand, outsourced pharma services and ethanol and glycol use keep adding volumes for these firms. Three drivers stand out.

Branded medicines: Doctors prescribe trusted generic brands.
Pharma services: Drug makers outsource commercial and regulatory work.
Renewable chemicals: Ethanol and glycols find wider industrial use.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 28.43 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Indegene: Life Sciences Outsourcing Anchors the Roadmap

Indegene's roadmap rests on commercial, medical and regulatory services for life sciences and pharma companies, with outsourcing by drug makers supporting revenue.

Revenue grew from Rs 1,690.50 crore in FY22 to Rs 3,582.50 crore in FY26, a 111.9% rise, and FY26 revenue was 21.6% higher than FY25. FY26 net profit was Rs 401.10 crore. In Q1 FY27, revenue grew 39.5% to Rs 1,092.10 crore. Operating margin was 19.11% in FY26.

Debt to equity is 0.05 and return on equity is 12.78%. FY26 operating cash flow was Rs 650.80 crore against capital expenditure of Rs 44.30 crore. Indegene paid a dividend of Rs 2.25 per share for FY26, a yield of 0.38%. At a P/E of 35.20 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: The P/E of 35.20 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

India Glycols: Green Chemicals and Ethanol Build the Next Leg

India Glycols' roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.

Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.

Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.

What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Branded Generics, Life Sciences Services and Glycol Stocks in India: Alkem vs Indegene vs India Glycols on Key Financials

Among the best branded generics, life sciences services and glycol stocks in India, Alkem leads on FY26 operating margin and return on equity; Indegene leads on FY26 revenue growth and Q1 FY27 revenue growth; India Glycols leads on the lowest P/E and dividend yield. The table puts the numbers side by side.

Metric	Alkem	Indegene	India Glycols
FY26 revenue (Rs Cr)	15,295.62	3,582.50	4,216.34
FY26 revenue growth	13.7%	21.6%	11.5%
FY26 net profit (Rs Cr)	2,353.13	401.10	292.76
FY26 operating profit margin	23.20%	19.11%	7.12%
Q1 FY27 revenue growth (YoY)	11.0%	39.5%	19.3%
Return on equity	16.66%	12.78%	9.98%
P/E ratio	28.43	35.20	7.58
Debt to equity	0.15	0.05	0.58
Dividend yield	1.01%	0.38%	2.10%
FY26 operating cash flow (Rs Cr)	1,963.03	650.80	769.16

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Branded Generics, Life Sciences Services and Glycol Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen branded generics, life sciences services and glycol stocks and shortlist branded generics, life sciences services and glycol stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and cash flow together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these branded generics, life sciences services and glycol stocks

Risks to Consider Before Investing in Branded Generics, Life Sciences Services and Glycol Stocks

Consumer demand: Spending patterns can shift sales between quarters.
Input costs: Changes in raw material prices can affect margins.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Alkem, Indegene and India Glycols live.

Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover branded generics, pharma services and glycols. Alkem leads on FY26 operating margin and return on equity; Indegene leads on FY26 revenue growth and Q1 FY27 revenue growth; India Glycols leads on the lowest P/E and dividend yield.

Across branded generics, life sciences services and glycol stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the branded generics, life sciences services and glycol stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Branded Generics, Life Sciences Services and Glycol Stocks

Which are the best branded generics, life sciences services and glycol stocks in India with a strong roadmap?

Ans. Alkem Laboratories, Indegene and India Glycols stand out for their roadmaps in branded generics, pharma services and glycols. FY26 revenue growth was 13.7% at Alkem, 21.6% at Indegene and 11.5% at India Glycols, and return on equity ranges from 9.98% to 16.66%.

Is Alkem Laboratories a good stock to buy now?

Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Alkem, Indegene and India Glycols?

Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 35.20 for Indegene (industry 62.79) and 7.58 for India Glycols (industry 54.53). All of them trade below the industry multiple.

Which of these branded generics, life sciences services and glycol stocks has the highest return on equity?

Ans. Alkem Laboratories has the highest return on equity at 16.66%, followed by Indegene at 12.78% and India Glycols at 9.98%.

What are the risks of investing in branded generics, life sciences services and glycol stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Alkem, Indegene and India Glycols perform in Q1 FY27?

Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. Indegene reported revenue of Rs 1,092.10 crore, up 39.5% year on year. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore.

Do branded generics, life sciences services and glycol stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 1.01% for Alkem, 0.38% for Indegene and 2.10% for India Glycols, based on dividends declared for FY26.

How can I invest in branded generics, life sciences services and glycol stocks in India?

Ans. You can buy branded generics, life sciences services and glycol stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.